May the Risk of PHLF be Predicted With Preoperative Liver Gadoxetate MRI
Launched by UNIVERSITY HOSPITAL, LINKOEPING · Dec 30, 2020
Trial Information
Current as of July 09, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how a specific type of MRI, called Gadoxetate MRI, can help predict the risk of a serious complication called post hepatectomy liver failure (PHLF) after liver surgery. PHLF can happen when the liver doesn’t recover properly after a part of it is removed, which can lead to serious health issues. The researchers want to see if this MRI can provide better information about how well the liver is functioning before surgery, making it easier for doctors to assess which patients might be at higher risk for complications.
To be eligible for this trial, participants need to be adults aged 18 or older who have had a Gadoxetate MRI (also known as Primovist MRI) within a certain timeframe before their liver surgery. This includes patients with cirrhosis (a liver condition) or those who have had specific types of liver volume treatments. Participants will be asked to share their medical information and the results of their MRIs to help researchers understand the relationship between liver function and the risk of PHLF. It’s important to know that this study is currently recruiting participants and aims to improve safety and outcomes for future liver surgery patients.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Patients who have had a Primovist MRI within 8 weeks before hemihepatectomy or extended hemi-hepatectomy +/- bile duct anastomosis independent of diagnosis.
- • 2. Patients with cirrhosis who have had a Primovist MRI within 8 weeks before resection of more than one liver segment
- • 3. Patients who had liver volume augmentation with a pre-operative Primovist MRI less than 2 weeks before resection
- • 4. Patients who have had a Primovist MRI within 6 weeks be-fore any liver resection where PHLF or death within 90 days occurred.
- • -
- Exclusion Criteria:
- • 1. \<18 years of age
- • 2. Resection was not performed -
About University Hospital, Linkoeping
The University Hospital in Linköping is a leading academic medical center renowned for its commitment to advancing healthcare through innovative research and clinical trials. As a pivotal institution within the region, it integrates cutting-edge medical practices with academic excellence, facilitating a collaborative environment for healthcare professionals and researchers. The hospital actively participates in a wide range of clinical trials across various medical disciplines, aiming to enhance patient outcomes and contribute to the global body of medical knowledge. With a focus on ethical standards and patient safety, the University Hospital in Linköping is dedicated to pioneering solutions that address pressing health challenges.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Göteborg, , Sweden
Uppsala, , Sweden
Oslo, , Norway
Stockholm, , Sweden
Copenhagen, , Denmark
Helsinki, , Finland
Linköping, Ostergotland, Sweden
Stockholm, Södermanland, Sweden
Patients applied
Trial Officials
Per Sandström, Prof
Principal Investigator
Academic study
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials